Introduction
Approximately 40 ± 50% of breast cancer has been found to overexpress epidermal growth factor receptor (EGFR) and ErbB2 (also known as HER2/NEU) receptor tyrosine kinases (RTKs) (Harris et al., 1989; Jardines et al., 1993; Koenders et al., 1992; Slamon et al., 1987) . The EGFR protein is frequently overexpressed in breast cancer without gene ampli®cation, while the erbB2 protein is often overexpressed with gene ampli®cation (Jardines et al., 1993) . Increased expression of EGFR or ErbB2 has been associated with poor survival prognosis in breast cancer patients (Koenders et al., 1992; Slamon et al., 1987) . This is probably related to the association of EGFR and ErbB2 with increased cell growth (Cance and Liu, 1995; Chrysogelos and Dickson, 1994; Di Fiore et al., 1987; Ennis et al., 1989; Fitzpatrick et al., 1984; Hudziak et al., 1987; Velu et al., 1987) , enhanced metastatic potential (Tan et al., 1997) and, in some cases, increased resistance to hormonal or chemotherapy (Cance and Liu, 1995; Nicholson et al., 1988; Pietras et al., 1995; Yu et al., 1996) .
Both EGFR and ErbB2 are type 1 RTKs that have intrinsic tyrosine kinase activities (Pawson, 1995; Schlessinger and Ullrich, 1992; Ullrich and Schlessinger, 1990) . Their overall homology is 50% while their cytoplasmic (kinase activity) homology is 80% (Bargmann et al., 1986) . EGFR is activated upon binding to its ligands, such as epidermal growth factor (EGF) and TGF-a (Pawson, 1995; Schlessinger and Ullrich, 1992) . There is no known ligand for ErbB2, but its activation is believed to be due to its overexpression (Akiyama et al., 1986; DiGiovanna and Stern, 1995) . Upon activation, either by ligand binding or protein overexpression, dimerization and stabilization of RTKs occur, resulting in stimulation of tyrosine kinase activities and autophosphorylation on tyrosine residues (Downward et al., 1984; Hazan et al., 1989; Margolis et al., 1989) . Phosphotyrosine residues could then be used as docking sites for various proteins (Heldin, 1996; Pawson, 1995; Schlessinger and Ullrich, 1992) . One such protein is the growth factor receptor bound protein-2 (Grb2) (Lowenstein et al., 1992; Suen et al., 1993) .
Grb2 is an adaptor protein whose main purpose is to link RTKs with their downstream signaling molecules. Grb2 has one Src homology 2 (SH2) domain¯anked by two SH3 domains (Buday and Downward, 1993a,b; Lowenstein et al., 1992; Suen et al., 1993) . It is through these SH domains that Grb2 links all these signaling proteins together. Grb2 uses its SH2 domain to bind to phosphotyrosine residues found in EGFR or ErbB2, while it uses its SH3 domains to bind to proteins containing proline-rich motifs, such as Son of Sevenless (Sos) (Buday and Downward, 1993a,b; Lowenstein et al., 1992; Suen et al., 1993) . Sos is a guanine nucleotide exchange factor, and is a positive regulator of Ras (Bon®ni et al., 1992; Bowtell et al., 1992) . Ras is important for the regulation of various cellular processes, such as gene transcription and cellular proliferation. Therefore upon EGFR or ErbB2 activation, Grb2 is used to recruit Sos to the membrane to stimulate Ras Rozakis-Adcock et al., 1993) , which will lead to the activation of Ras/Raf/MEK/mitogen-activated protein (MAP) kinase (also known as extracellular signalregulated kinase, ERK) (Gardner et al., 1993; Marais and Marshall, 1996) . Activated MAP kinase will then induce gene transcription and cell proliferation (Marais and Marshall, 1996; Treisman, 1996) . EGFR and ErbB2 activation can also increase the tyrosine phosphorylation of other proteins, such as the SH2 domain-containing a2 collagen-related protein (Shc) (Batzer et al., 1994; Segatto et al., 1993; SeppLorenzino et al., 1996) . Phosphorylated Shc may also be used to bind to Grb2/Sos and activate the Ras/Raf/ MEK/MAP kinase pathway.
Grb2 protein overexpression and/or GRB2 gene ampli®cation have been reported in human breast cancer cell lines . Since increased Grb2 expression has been correlated with increased oncogenic signaling, it is believed that Grb2 is vital for breast tumorigenesis . Grb2 is necessary for the transformation of ®broblasts and breast epithelial cells by EGFR and ErbB2 (Lowenstein et al., 1992; Suen et al., 1993; Xie et al., 1995) . However, it is not clear whether Grb2 is also important for the proliferation of breast cancer cells as regulated by these RTKs. Here, we have studied the eects of Grb2 protein downregulation on the proliferation and MAP kinase inactivation in breast cancer cells expressing EGFR and ErbB2.
Results
Liposomal Grb2 antisense oligos (L-Grb2) inhibited the proliferation of EGFR-overexpressing breast cancer cells in an EGF-dependent manner MDA-MB-468 cells overexpress EGFR as a result of gene ampli®cation (Filmus et al., 1985) . These cells do not need any exogenous growth factors to grow when cultured in the presence of fetal calf serum (FCS). However, their growth rate may be modulated by the amount of serum or growth factors used (Filmus et al., 1985) . MDA-MB-468 cells grew faster in the presence of 10 versus 0.5% FCS, and their growth could be modulated upon addition of exogenous EGF. Low doses of EGF stimulate MDA-MB-468 cell growth while high doses of EGF are growth-inhibitory (Filmus et al., 1985) . Under our culture conditions, EGF did not inhibit the growth of MDA-MB-468 cells.
MDA-MB-468 cells were incubated with L-Grb2 or liposomal control oligos (L-control) for 5 days in the presence of 10 or 0.5% FCS (Figure 1 ). At the end of the incubation, cell growth was determined and the growth of treated cells was compared with that of untreated cells cultured under the same serum conditions. L-Grb2 could suppress the growth of MDA-MB-468 cells in either serum condition, but higher in 10% FCS. At 12 mM concentrations of LGrb2, the growth of MDA-MB-468 cells was reduced to 73 and 55% in 10 and 0.5% FCS, respectively. In the presence of 0.5% FCS, EGF could be added and used as a ligand to stimulate EGFR kinase activity, thereby stimulating cell growth. Eighty ng/ml of EGF was more eective than 40 ng/ml of EGF in inducing cell growth. MDA-MB-468 cells were incubated with L-Grb2 or L-control for 2 days before 0 ± 80 ng/ml of EGF was added. The cells were then left to incubate with liposomal oligos and EGF for 3 more days before cell growth was determined. Growth of treated cells was compared with that of untreated cells cultured under the same EGF concentrations. L-Grb2 induced dose-dependent growth inhibition in MDA-MB-468 cells. At 12 mM concentrations of L-Grb2, the growth of MDA-MB-468 was decreased to 73, 38 and 24% of untreated cells cultured in 0, 40 and 80 ng/ml of EGF, respectively. In other words, growth inhibition increased, from 27% to 62 ± 76%, with increasing concentrations of EGF. Under identical conditions, L-control inhibited cell growth between 14 ± 32% ( Figure 1b) .
Even at the same EGF dose, EGFR can be increasingly activated when the time of EGF incubation is increased. Therefore, we tested the inhibitory eects of L-Grb2 on MDA-MB-468 cell growth when the incubation time of EGF was varied between 1 ± 5 days. The growth inhibitory eects of L-Grb2 on MDA-MB-468 cells were dependent on the time of EGF incubation; growth inhibition increased with increasing time of EGF incubation ( Figure 2 ). When MDA-MB-468 cells were incubated with 12 mM of LGrb2 and 1 day of EGF, cell growth was decreased by 67%. However when L-Grb2 concentration were kept at 12 mM but EGF incubation was increased to 3 and 5 days, MDA-MB-468 cell growth was further reduced by 84 and 100%, respectively. At the highest L-control used, 22 ± 36% of growth inhibition was observed. These results demonstrate that L-Grb2 can inhibit the Figure 1 L-Grb2 selectively inhibited the proliferation of breast cancer cells that express high levels of EGFR in an EGFdependent manner. MDA-MB-468 cells were incubated with (a) L-Grb2 or (b) L-control for 5 days between 0 ± 14 mM ®nal concentrations in either 10 or 0.5% FCS. During the last 3 days of incubation, 0, 40 or 80 ng/ml EGF was also added. At the end of the incubation, cell growth and viability of breast cancer cells was measured by the alamarBlue dye (Alamar Sciences, Sacramento, CA, USA) incorporation assay similar to that described previously (Tari et al., 1997) . Growth of treated cells was compared with that of untreated cells cultured under the same FCS and EGF conditions, and was expressed as per cent of untreated cells proliferation of EGFR-overexpressing breast cancer cells in an EGF-dependent manner.
L-Grb2 inhibited the proliferation of breast cancer cells that express high, but not low, levels of ErbB2
There is no known ligand for ErbB2; however ErbB2's activity could be modulated by its endogenous level of expression (Janes et al., 1994; Kallioniemi et al., 1992) . We have used four dierent breast cancer cell lines that either express high or low levels of ErbB2 (Figure 3 ). Both SKBr3 and MDA-MB-453 breast cancer cell lines have HER2/NEU gene ampli®cation and express high levels of ErbB2 protein (Figure 3 ). ErbB2 tyrosine kinase is constitutively active in these cells (Janes et al., 1994) . SKBr3 and MDA-MB-453 cells were incubated with increasing concentrations of L-Grb2 or L-control for 5 days. A dose-dependent decrease in cell growth was found in both SKBr3 and MDA-MB-453 cells incubated with L-Grb2 (Figure 4) . When SKBr3 cells were incubated with 12 mM of L-Grb2 for 5 days, the growth of SKBr3 cells decreased by 100% (IC 50 =8 mM). Similarly, when MDA-MB-453 cells were incubated with L-Grb2, the growth of MDA-MB-453 cells decreased by 90% at 14 mM of L-Grb2 concentrations (IC 50 =10 mM). Conversely, when SKBr3 and MDA-MB-453 cells were incubated with L-control under identical conditions, the growth of both cell lines was not decreased (Figure 4) .
We then studied the eects of L-Grb2 and L-control on the proliferation of MCF-7 and MDA-MB-435 breast cancer cell lines which do not have HER2/NEU gene ampli®cation and express only low levels of ErbB2 protein (Figure 3 ). ErbB2 tyrosine kinase is inactive in these cells (Janes et al., 1994) . Both L-Grb2 and L-control did not signi®cantly decrease the growth of MCF-7 and MDA-MB-435 cells ( Figure 5 ). Even when 14 mM concentrations of L-Grb2 were used, the growth of MCF-7 and MDA-MB-435 cells only decreased by 20%. These results demonstrate that L- Grb2 can selectively inhibit the proliferation of breast cancer cells which express high levels of ErbB2. In other words, growth inhibition was only observed in breast cancer cells whose ErbB2 tyrosine kinase is active.
L-Grb2 speci®cally inhibited the expression of Grb2 proteins
Western blots were performed to determine whether LGrb2 could speci®cally inhibit production of Grb2 proteins. All the above cell growth studies were done with control oligo #1. To ensure that L-Grb2 was selectively inhibiting the Grb2 protein and the controls were working appropriately, we had used a dierent control oligo (control oligo #2) for the Western blot studies. SKBr3 cells were incubated with 6 ± 8 mM of liposomal oligos for 3 days ( Figure 5 ). Breast cancer cells were then lysed and analysed by Western blotting. Densitometric scans were used to quantitate the ratio of Grb2 protein to another SH2/SH3 adaptor protein, Crkl, so that the per cent of Grb2 protein inhibition could be determined. When SKBr3 cells were incubated with 6 ± 8 mM of L-Grb2, the expression of Grb2 protein was decreased by 13 ± 45% (Figure 6a ). The inhibition of Grb2 protein expression was selective since L-control did not inhibit the expression of Grb2 proteins. Neither L-Grb2 nor L-control signi®cantly inhibited the levels of the control Crkl protein ( Figure  6 ).
Though MCF-7 cell growth was not inhibited by LGrb2, Western blots were performed to determine the extent of Grb2 inhibition in MCF-7 cells. When MCF-7 cells were incubated with 8 and 10 mM of liposomal oligos for 3 days, selective Grb2 protein inhibition was observed. Grb2 protein inhibition was approximately 27 ± 41% (Figure 6b ). Liposomal oligos did not inhibit the expression of the control Crkl protein.
Grb2 protein inhibition led to inactivation of MAP kinase in EGFR-overexpressing, but not in ErbB2-overexpressing, breast cancer cells
Since Grb2 is believed to be important for the transduction of RTK signals to Ras and, ultimately, MAP kinase, we have tried to correlate the mechanism of Grb2 inhibition with MAP kinase inactivation. To determine the activation levels of MAP kinase, we have used Western blots in conjunction with antibodies speci®c for the dual phosphorylated active MAP kinases (p44 ERK1 and p42 ERK2) (Duesbery et al., 1998; Majeti et al., 1998; Yablonski et al., 1998) . Densitometric scanning was used to quantitate the activation levels of MAP kinases (active ERK1,2) in relation to the amount of MAP kinase proteins present. MDA-MB-468 cells were incubated with 6 mM of liposomal oligos for 3 days in the presence of 80 ng/ml EGF and 0.5% FCS. L-Grb2 selectively downregulated Grb2 protein expression, and selectively downregulated activation of ERK1,2 in MDA-MB-468 cells (Figure 7a ). Compared with untreated cells, samples treated with 6 mM L-Grb2 had a 41% decrease in Grb2 protein expression and a 35% decrease in ERK1,2 activation levels.
To study the eects of Grb2 inhibition on MAP kinase activation in ErbB2-overexpressing breast cancer cells, we had used the same protein lysates in which Grb2 protein downregulation was observed (Figure 6a) . In contrast to MDA-MB-468 cells, no changes were observed with the activation levels of MAP kinase (55%) in SKBr3 cells (Figure 7b) , nor in the other ErbB2-overexpressing breast cancer cell line, MDA-MB-453 (data not shown).
Discussion
Grb2 has long been known to be a key downstream protein in signal transduction as initiated by various RTKs. Loss of function mutations in the Drosophila and Caenorhabditis elegans homologues of GRB2 disrupt signaling by the Sevenless and Let-23 receptor tyrosine kinases, respectively, and the mutant phenotypes can be speci®cally rescued by expression of wildtype GRB2 (Clark et al., 1992; Simon et al., 1991 Simon et al., , 1993 Stern et al., 1993) . Grb2 is critical for the transformation of ®broblasts by RTKs (Lowenstein et al., 1992; Pendergast et al., 1993; Xie et al., 1995) , and for the proliferation of chronic myelogenous leukemic cells, which are regulated by the constitutively active Bcr-Abl tyrosine kinase (Tari et al., 1997) .
Our data indicate that Grb2 protein is also vital for the proliferation of breast cancer cells that express EGFR or ErbB2 tyrosine kinases, and that the degree of growth inhibition is dependent on the activation levels of the RTKs. Upon ligand binding stimulation, activation of EGFR occurs, which leads to increased association with Grb2, enhanced oncogenic signaling and increased cell growth (Pawson, 1995; Schlessinger and Ullrich, 1992) . Conversely, when phosphorylation of EGFR is inhibited, EGFR signaling is disrupted and growth inhibition occurs (Baselga et al., 1993; Ennis et al., 1989) . Here we used a dierent strategy to inhibit the growth of EGFR-expressing breast cancer cells: we disrupted the downstream tyrosine kinase signaling of EGFR by downregulating Grb2 protein expression.
Exogenous ligand was not used to stimulate ErbB2 kinase activity since there is no known ligand for ErbB2. However ErbB2's activity could be modulated by its endogenous level of expression. ErbB2 is activated when it is expressed at very high levels (Janes et al., 1994) . Overexpression of ErbB2 enhances dimer formation which results in constitutive activation of ErbB2, increased association with Grb2, and increased oncogenic signaling (Janes et al., 1994) . On the other hand, when ErbB2 expression is low, it is inactive, as it cannot form dimers as readily. Inactive ErbB2 cannot associate with Grb2 proteins and will not be able to use Grb2 for signal transduction. Indeed, we found that Grb2 downregulation could lead to selective growth inhibition in breast cancer cell lines that express high, but not low, levels of ErbB2. This is not surprising as only breast cancer cells that express high levels of ErbB2 are expected to use the Grb2 protein. This ®nding is also quite similar to our other ®ndings in which emodin, a tyrosine kinase inhibitor, was found to be more eective against breast cancer cells overexpressing ErbB2 than those cells expressing basal levels of ErbB2 (Zhang et al., 1995) .
There has been much evidence demonstrating that Grb2 is being used by RTKs to activate the Ras/Raf/ Mek/MAP kinase pathway. Therefore, we hypothesize that Grb2 inhibition will lead to MAP kinase inactivation. We found that Grb2 inhibition could indeed lead to the inactivation of MAP kinase in EGFR cells. However, Grb2 inhibition did not lead to MAP kinase inactivation in ErbB2 cells. Interestingly this is similar to what we have observed in another ErbB2-related system: when dominant negative Shc mutants were used to inhibit ®broblasts transformation by HER2/NEU, no changes were observed in the level of MAPK activation even though transformation was inhibited (Li et al., 1998) . These data suggest that EGF-stimulated EGFR signal and ErbB2 overexpression-mediated signal may use dierent mechanisms in regulating breast tumorigenesis; EGF-stimulated EGFR growth signal is MAP kinase dependent while ErbB2 overexpression-mediated growth signal is MAP kinase independent. One possible mechanism used by ErbB2 to regulate cell growth is via phosphoinositol-3 kinase, since ErbB2 can activate phosphoinositol-3 kinase (Peles et al., 1992; Ram and Ethier, 1996) which has been correlated with transformation and cell growth (Alimandi et al., 1995; Roche et al., 1994; Skorski et al., 1995) and has been shown to be a downstream signaling molecule of Ras (Hu et al., 1995; Rodriguez-Viciana et al., 1994 . It has been proposed that the mitogenic and transforming actions of Ras may be mediated through both the MAP kinase and the phosphoinositol-3 kinase pathways .
Grb2 is one of the most common adaptor proteins used by RTKs for signal transduction. We have reported that Grb2 protein downregulation can lead to inhibition of chronic myelogenous leukemic cell growth as regulated by the Bcr-Abl tyrosine kinase (Tari et al., 1997) . Our present data indicates that downregulation of Grb2 protein expression can also lead to growth inhibition in breast cancer cells that express high levels of EGFR or ErbB2 tyrosine kinases. These ®ndings strongly suggest that Grb2 plays a vital role in tumorigenesis, and may have strong implications for novel treatment strategies.
Materials and methods

Cell lines
Breast cancer cell lines such as MDA-MB-468, SKBr3, MDA-MB-453, MCF-7 and MDA-MB-435 cells were used. MDA-MB-468 cells have high levels of EGFR (Filmus et al., 1985) . SKBr3 and MDA-MB-453 cells have high levels of ErbB2, while MCF-7 and MDA-MB-435 cells express low levels of ErbB2 (Janes et al., 1994; Kallioniemi et al., 1992) . All cells were cultured in DMEM/F12 medium supplemented with 10% heat-inactivated fetal bovine serum at 378C under 5% CO 2 in a humidi®ed incubator.
Antibodies
Monoclonal antibodies speci®c for ErbB2 and Actin were purchased from Neomarkers and Oncogene, respectively. Murine antibodies speci®c for Grb2 and rabbit antibodies speci®c for Crkl were obtained from Transduction Laboratories, and Santa Cruz, respectively. Rabbit antibodies speci®c for MAP kinase and active ERK1,2 proteins were purchased from Oncogene and New England Biolabs, respectively. The latter antibody recognizes only active, but not inactive, ERK1,2 (Duesbery et al., 1998; Majeti et al., 1998; Yablonski et al., 1998) . Anti-mouse or anti-rabbit secondary antibodies conjugated with horseradish peroxidase were obtained from Amersham.
Oligos
Nuclease-resistant P-ethoxy oligos were purchased from Oligos Etc. and were incorporated into liposomes as described (Tari et al., 1997) . The oligo sequences had previously been described (Tari et al., 1997) , and are:
Grb2 antisense: 5'-ATATTTGGCGATGGCTTC-3' Control oligo #1: 5'-GGGCTTTTGAACTCTGCT-3' Control oligo #2: 5'-TCGCCACTCGATCCTGCCCG-3'
Preparation of liposomal oligos
Liposomal oligos were prepared as described (Tari et al., 1997) . P-ethoxy oligos were mixed with phospholipids in the presence of excess t-butanol (595%). The mixture was vortexed, frozen in an acetone/dry ice bath and then lyophilized. The lyophilized preparation was kept at 7208C until ready for use. The preparation was then hydrated with normal 0.9% saline.
Assay of cell viability
Breast cancer cells were seeded at 1.0 ± 2.5610 3 cells/well in 96-well plates in 0.1 ml of medium. Cells were incubated with liposomal oligos for 5 days between 0 ± 14 mM ®nal concentrations. At the end of the incubation, growth of breast cancer cells was measured by the alamarBlue dye (Alamar Sciences, Sacramento, CA, USA) incorporation assay as described (Tari et al., 1997) . Growth of breast cancer cells treated with liposomal oligos were compared with those of untreated controls. Growth inhibitory eects are de®ned as a decrease in viability due to reduced incorporation of the alamarBlue dye by the breast cancer cells. Each experiment was done in triplicate and repeated at least ®ve times.
Western blot
Fifty mg of protein lysates from SKBr3, MDA-MB-453, MDA-MB435, and MCF-7 cells were loaded on a 7.5% SDS ± PAGE to study the expression of ErbB2 and Actin proteins in these breast cancer cell lines. Proteins were then transferred to a nitrocellulose membrane. The membrane was incubated with ErbB2 mouse antibody and then incubated with anti-mouse secondary antibody. After visualizing ErbB2 protein by enhanced chemiluminescence system (Amersham), the membrane was stripped and reprobed with anti-Actin antibody. Actin protein was also visualized by enhanced chemiluminescence.
Breast cancer cells, plated in a 6-well plate in 1.5 ml of medium, were incubated with 6 ± 10 mM of liposomal oligos. Untreated cells were also maintained in culture. Cell samples were removed on day 3 after the addition of liposomal oligos. Cell lysates were prepared and normalized for total protein content. Five to eight mg of proteins were used to study Grb2 and Crkl proteins expression, while 15 ± 20 mg of proteins were used to study MAP kinases, and activated MAP kinases (i.e. active ERK1,2). After mixing the lysates with SDScontaining sample buer, protein lysates were loaded in a 12% polyacrylamide gel. SDS ± PAGE and transfer of proteins to nitrocellulose membranes were done. The Grb2/ Crkl membrane was cut in half so that the top and the bottom portions of the membrane could be incubated with Crkl and Grb2 antibodies, respectively. Membranes were then incubated with the appropriate secondary antibodies, and protein bands were visualized by enhanced chemiluminescence. The MAP kinase membrane was incubated with anti-MAP kinase antibodies, stripped, and then reincubated with anti-active ERK1,2 antibodies. After incubating with anti-rabbit secondary antibodies, protein bands were also visualized by enhanced chemiluminescence. Images were scanned with Personal Densitometer (Molecular Dynamics), and protein bands were quantitated by using the ImageQuant application program.
